52344
document
Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome : clinical and instrumental evaluation . BACKGROUND Despite it is accepted that acne is mostly caused by an hyper-responsiveness of the pilo-sebaceous unit to normal circulating androgen hormones , in a few patients , especially women , acneic lesions can be associated with increased serum androgen levels ( hyperandrogenism ) , of which polycystic ovary syndrome ( PCOS ) is the most common cause . In women with acne and proven PCOS therapy with estroprogestins ( EPs ) can be an excellent option . OBJECTIVE The aim of the study was to assess the effects of two estroprogestins ( EPs ) , ethinyl-estradiol ( EE ) 30 mcg/drospirenone ( DRSP ) 3 mg , and ethinyl-estradiol ( EE ) 30 mcg/chlormadinone acetate ( CMA ) 2 mg , both on increased serum androgen levels and on several skin parameters in women affected by mild to severe acne and polycystic ovary syndrome ( PCOS ) . METHODS Fifty-nine women were randomized to receive EE/DRSP ( n = 32 ) or EE/CMA ( n = 27 ) for six months . Evaluation of serum androgen levels , grading of acne and hirsutism ( respectively with Pillsbury and Ferriman-Gallwey score ) and non-invasive assessment of skin hydration , transepidermal water loss ( TEWL ) and skin homogeneity were performed at baseline , at 3 and 6 months ( end of treatment ) . RESULTS Both treatments were well tolerated and showed a significant improvement of skin and hormonal parameters , although EE/DRSP showed a more potent effect on acne and seborrhea . CONCLUSIONS Estroprogestins represent an effective and safe treatment in women with acne and polycystic ovary syndrome ( PCOS ) . Nevertheless , the combination EE 30 mcg/DRSP 3 mg appears to be a more potent therapeutic option .
52345
Intervention_Pharmacological
oestroprogestins
52346
Intervention_Pharmacological
estroprogestins ( EPs )
52347
Intervention_Pharmacological
estroprogestins ( EPs )
52348
Intervention_Pharmacological
ethinyl-estradiol ( EE ) 30 mcg/drospirenone ( DRSP ) 3 mg
52349
Intervention_Pharmacological
ethinyl-estradiol ( EE ) 30 mcg/chlormadinone acetate ( CMA ) 2 mg
52350
Intervention_Pharmacological
EE/DRSP
52351
Intervention_Pharmacological
EE/CMA
52352
Intervention_Pharmacological
EE/DRSP
52353
Intervention_Pharmacological
Estroprogestins
52354
Intervention_Pharmacological
EE 30 mcg/DRSP 3 mg
52355
Outcome_Physical
Skin improvement
52356
Outcome_Physical
serum androgen levels
52357
Outcome_Physical
serum androgen levels
52358
Outcome_Physical
skin parameters
52359
Outcome_Physical
serum androgen levels , grading of acne and hirsutism
52360
Outcome_Physical
non-invasive assessment of skin hydration , transepidermal water loss ( TEWL ) and skin homogeneity
52361
Outcome_Physical
skin and hormonal parameters
52362
Outcome_Physical
acne and seborrhea .
52363
Outcome_Other
effective and safe treatment
52364
Outcome_Other
potent therapeutic option
52365
Participant_Condition
acne
52366
Participant_Condition
polycystic ovary syndrome :
52367
Participant_Sex
women
52368
Participant_Sex
women
52369
Participant_Condition
acne
52370
Participant_Sex
women
52371
Participant_Condition
mild to severe acne
52372
Participant_Condition
polycystic ovary syndrome ( PCOS )
52373
Participant_Sample-size
Fifty-nine
52374
Participant_Sex
women
52375
Participant_Sex
women
52376
Participant_Condition
acne